SS-31 (Elamipretide) Review: Mitochondrial Peptide Benefits & Research (2026)

Quick Take: SS-31 (Elamipretide) from Ascension Peptides is $61 for 10mg — strong market value for one of the most scientifically compelling longevity peptides available. SS-31 targets the inner mitochondrial membrane with remarkable specificity, improving energy production and reducing oxidative damage at the cellular level. It's the peptide with the most human clinical data among the mitochondria-targeted compounds.

Mitochondrial dysfunction is a central driver of aging and age-related disease. As mitochondria accumulate damage — through oxidative stress, membrane degradation, and inefficient electron transport — cellular energy production declines, reactive oxygen species accumulate, and cells lose the capacity to maintain normal function. This process underlies fatigue, cognitive decline, cardiovascular aging, and numerous chronic conditions.

SS-31 (also known as Elamipretide, MTP-131, or Bendavia) is a tetrapeptide specifically engineered to target and stabilize the inner mitochondrial membrane. It's one of the few research compounds with both robust preclinical data and meaningful human clinical trial experience — making it uniquely credible in a longevity research space where most compounds have only animal data.

Ascension's SS-31 Offering

• SS-31 10mg — $61
• Third-party COA with HPLC purity ≥98% and mass spectrometry confirmation
• US domestic shipping

At $6.10/mg, pricing is competitive for a verified tier-1 source. SS-31 is available from several vendors at $50–$80 for 10mg; the pricing difference mostly reflects documentation quality. At $61 with Ascension's COA standards, this is reasonable value.

Mechanism: Why the Inner Mitochondrial Membrane?

SS-31 is a member of the Szeto-Schiller (SS) peptide family, developed by Dr. Hazel Szeto at Cornell. The peptide's design is elegant: it carries alternating aromatic and basic amino acid residues that give it high affinity for cardiolipin — a unique phospholipid found almost exclusively in the inner mitochondrial membrane.

Cardiolipin is essential for mitochondrial function. It:

• Maintains the structural integrity of the inner mitochondrial membrane
• Supports the supercomplexes of the electron transport chain (ETC) — the machinery that produces ATP
• Regulates cytochrome c, a key protein in both electron transport and apoptotic signaling
• Acts as a proton trap, maintaining the electrochemical gradient that drives ATP synthesis

With aging and oxidative stress, cardiolipin becomes oxidized — it loses its structural role and cytochrome c dissociates from the membrane, impairing electron transport and increasing ROS production. SS-31 binds to cardiolipin and prevents/reverses this oxidation, restoring membrane integrity and ETC supercomplex organization.

The result in research models: restored ATP production, reduced mitochondrial ROS generation, reduced cellular apoptosis from energy failure, and improved overall mitochondrial biogenesis signaling.

Clinical Research Data: Beyond Mouse Studies

SS-31's distinguishing feature is human trial experience — rare for compounds in the longevity research peptide space:

Heart Failure

The PROGRESS-HF trial examined SS-31 (as Elamipretide) in heart failure with preserved ejection fraction (HFpEF). Results showed significant improvements in 6-minute walk distance and patient-reported quality of life. This is noteworthy because HFpEF is driven substantially by mitochondrial dysfunction in cardiac muscle — exactly the pathology SS-31 targets.

Barth Syndrome

Barth syndrome is a rare genetic disease involving a cardiolipin mutation. SS-31 clinical trials in Barth patients showed significant functional improvements — a direct proof-of-concept for the cardiolipin mechanism in humans.

Aging Muscle

A 2020 study in Aging Cell demonstrated that SS-31 injection in older adults with skeletal muscle mitochondrial dysfunction improved mitochondrial respiration, reduced oxidative stress markers, and partially restored muscle energetics toward younger adult levels. This is some of the most direct anti-aging evidence available for any peptide in clinical research.

Research Applications

• Cardiac research: Ischemia-reperfusion injury, heart failure models, cardiac aging
• Skeletal muscle aging: Sarcopenia, exercise capacity, mitochondrial biogenesis
• Neurodegenerative research: Mitochondrial dysfunction is central to Alzheimer's, Parkinson's, and ALS models
• Kidney protection: Acute kidney injury models (SS-31 has extensive renal ischemia data)
• General longevity: Mitochondrial health as a fundamental aging biomarker
• Exercise and performance research: Mitochondrial capacity as a determinant of aerobic performance

Research Dosing

• Animal research: 0.1–3 mg/kg subcutaneous, often daily or every other day
• Human clinical trials: 0.05–0.25 mg/kg subcutaneous in most published protocols
• Practical at 10mg vial: At 70kg human-equivalent, 0.1 mg/kg = 7mg. The 10mg vial provides roughly 1–3 research administrations depending on the protocol dose
• Frequency: Daily to every other day in most protocols
• Duration: 4–12 weeks in most published research

SS-31 vs. Other Mitochondrial Peptides

SS-31 is the strongest choice for cardiac and kidney research. MOTS-c complements it for metabolic research — combining the two covers mitochondrial structural integrity (SS-31) and metabolic signaling (MOTS-c) from different angles.

Longevity Stack with SS-31

SS-31 pairs well with other longevity-focused peptides available from Ascension:

• SS-31 + MOTS-c: Mitochondrial structural integrity + metabolic signaling — comprehensive mitochondrial support
• SS-31 + Epithalon: Mitochondrial function + telomere maintenance — addresses two distinct hallmarks of aging
• SS-31 + FOXO4-DRI: Mitochondrial health + senescent cell clearance — addresses the cellular energy and zombie cell dimensions of aging simultaneously

FAQ

Why isn't SS-31 more widely known?

SS-31 (Elamipretide) was primarily developed for clinical pharmaceutical use — Stealth BioTherapeutics held the IP. After clinical trial results were mixed in some cardiac indications, the compound's pharmaceutical profile became less commercially compelling even as its basic science remained strong. This is why it's available as a research peptide with meaningful clinical data behind it — the mechanism is solid, the commercial pharmaceutical path just became complicated.

How does SS-31 compare to CoQ10 or NAD+ for mitochondrial support?

CoQ10 is an electron carrier in the ETC; NAD+ is an essential cofactor in cellular energy metabolism. SS-31 addresses the membrane architecture that makes both CoQ10 and NAD+-mediated processes work efficiently. The three operate at different levels of mitochondrial biology and are not redundant — some research protocols use all three for comprehensive mitochondrial support investigation.

Is the 10mg vial from Ascension enough for a meaningful research protocol?

At low doses (0.1–0.5mg per administration), 10mg provides 20–100 administrations — enough for a full research cycle. At higher doses, you'd need multiple vials. For initial research or dose-finding protocols, one vial is a reasonable starting point.

→ Source SS-31 from Ascension: Ascension Peptides

This content is for informational and educational purposes only. SS-31/Elamipretide is a research compound. While it has been studied in clinical trials, it is not FDA-approved for general human use. PeptideDeck may earn a commission from purchases through affiliate links at no additional cost to you.